Both medications can affect appetite, cardiovascular parameters, and gastrointestinal function, so individualised riskbenefit evaluation and regular review are essential
Laboratory models have recorded improvements in exercise tolerance, muscle performance, and metabolic balance following MOTS-c exposure under controlled conditions, making it a practical tool for geroscience and longevity research
Medicare will begin covering GLP-1 medications for obesity through the Medicare GLP-1 Bridge program starting July 1, 2026, offering eligible beneficiaries access for $50 per month
Beyond intestinal soap bile acids in metabolic control
Purity Testing and Analytical Methods Verified purity is the foundation of credible metabolic research
In the clinical trial, researchers found that many participants crossed below the obesity threshold entirely